Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.61 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | RGS12 | O14924 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28511682 | 0.86 | TAAR1 (0.52) | TAAR1AOC3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3624306 | 0.84 | TAAR1 (0.48) | TAAR1AOC3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28411588 | 0.80 | TAAR1 (0.45) | TAAR1AOC3CHRM2ADRA1AHSD17B10 | |
| SCHEMBL11478651 | 0.79 | HKDC1 (0.55) | TAAR1AOC3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4820239 | 0.78 | TAAR1 (0.41) | TAAR1SLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL598978 | 0.78 | TAAR1 (0.64) | TAAR1AOC3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL759880 | 0.76 | TAAR1 (0.61) | TAAR1SLC6A2SLC6A4SLC6A3PKM | |
| SCHEMBL247628 | 0.76 | TAAR1 (1.00) | TAAR1AOC3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9555066 | 0.76 | TAAR1 (0.61) | TAAR1AOC3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3088974 | 0.76 | TAAR1 (0.61) | TAAR1AOC3SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050148634-A1 | 1-N-Aminobenzimidazole derivatives | ZERIA PHARMACEUTICAL CO., LTD (JP) | 2005-07-07 | — | — | US | disclosed |
| US-6906078-B2 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | PHARMACIA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| US-6838465-B2 | N-acyltetrahydroisoquinoline derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-04 | — | — | US | disclosed |
| US-20040044031-A1 | N-acyltetrahydroisoquinoline derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| EP-1288202-A1 | N-ACYLTETRAHYDROISOQUINOLINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-03-05 | — | — | EP | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | disclosed |
| US-5686482-A | DOPAMINE RECEPTOR ANTAGONIST | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1997-11-11 | — | — | US | disclosed |
| CN-1147248-A | N- (3-pyrrolidinyl) benzamide derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 1997-04-09 | — | — | CN | disclosed |
| EP-0757985-A1 | N-(3-PYRROLIDINYL)BENZAMIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-02-12 | — | — | EP | disclosed |
| EP-0698010-A1 | N-ACYL SULFAMIC ACID ESTERS (OR THIOESTERS), N-ACYL SULFONAMIDES, AND N-SULFONYL CARBAMIC ACID ESTERS (OR THIOESTERS) AS HYPERCHOLESTEROLEMIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1996-02-28 | — | — | EP | disclosed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | disclosed |
| CN-1105354-A | Novel alkamine derivative and slat of same | YAMANOUCHI PHARMA CO LTD (JP) | 1995-07-19 | — | — | CN | disclosed |
| US-5185347-A | PIPERIDINE COMPOUNDS AND ANTIULCER COMPOSITION CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 1993-02-09 | — | — | US | disclosed |
| EP-0457331-A1 | Piperidine derivatives and antiulcer composition containing the same | MEIJI SEIKA KAISHA LTD. (JP) | 1991-11-21 | — | — | EP | disclosed |
| EP-0425134-A1 | Condensed pyrrolo derivatives, process for their preparation and pharmaceutical compositions containing them | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1991-05-02 | — | — | EP | disclosed |
| US-4987132-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| CN-1030415-A | Saturated heterocycle carboxamide derivatives and its preparation method | YAMANOUCHI PHARMA CO LTD (JP) | 1989-01-18 | — | — | CN | disclosed |
| US-4772619-A | ANTIULCER AGENTS | G. D. SEARLE & CO. (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0279681-A2 | Saturated heterocyclic carboxamide derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044031-A1 | N-acyltetrahydroisoquinoline derivatives | HCRTR2, HCRTR1, OPRL1 | TAAR1 52/4885AOC3 616/4885SLC6A2 814/4885 |
| US-20050148634-A1 | 1-N-Aminobenzimidazole derivatives | CYP1B1, CYP2E1, CYP1A1 | TAAR1 2771/4885AOC3 364/4885SLC6A2 3041/4885 |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | TAAR1 1705/4885AOC3 1014/4885SLC6A2 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.